AEON Biopharma, Inc. (AEON) Form 8-K — Aug 12, 2026
AEON Biopharma reported a second-quarter 2026 net loss of $1.155 million, or $0.02 per share, narrowing sharply from a $6.642 million loss a year earlier, with cash and cash equivalents of $3.4 million at June 30, 2026. The company completed an underwritten public offering in July 2026 with gross proceeds of approximately $15.3 million ($13.6 million net), plus milestone warrants that could deliver an additional $34.0 million in gross proceeds; upfront proceeds fund operations only into the first quarter of 2027.
Key figures
- Cash Position
- 3400000
- Shares Outstanding
- 26307211
- Cash runway
- into the first quarter of 2027
- Total assets usd
- 5910000
- Total liabilities usd
- 21271000
- Jeuveau 2025 sales usd
- 272300000
- Q2 2026 rd expense usd
- 2938000
- Q2 2026 sga expense usd
- 2991000
- Warrant liabilities usd
- 11367000
- Pre funded warrants outstanding
- ~48.2M
- Time based warrants outstanding
- ~18.4M (weighted avg exercise price $4.97)
- Us therapeutic neurotoxin market
- $3.5B in 2026, 7.7% CAGR to $5.1B by 2031 (Clarivate)
- Botox therapeutic market share 2025
- ~92% (91.9% per presentation)
- July 2026 offering net proceeds usd
- 13600000
- Milestone based warrants outstanding
- ~98.2M (weighted avg exercise price $0.35)
- July 2026 offering gross proceeds usd
- 15300000
- Shares outstanding per aug 2026 presentation
- ~49.9M
- Milestone warrant potential gross proceeds usd
- 34000000
Price after filing
Close on the filing date to close N calendar days later (from $0.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.